Vivos Inc. announced that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on January 15,2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.158 USD | +5.33% | +48.36% | +118.53% |
1st Jan change | Capi. | |
---|---|---|
+118.53% | 58.48M | |
-3.22% | 14.6B | |
-36.36% | 2.71B | |
-12.35% | 2.44B | |
-12.00% | 1.51B | |
-.--% | 1.12B | |
+40.35% | 518M | |
+89.74% | 502M | |
+12.77% | 239M | |
+1.30% | 183M |
- Stock Market
- Equities
- RDGL Stock
- News Vivos Inc.
- Vivos Inc Files A New Patent on Alternate Particles for Precision Radionuclide Therapy